Betty Nanzigu Mwesigwa
Institution: Makerere University Walter Reed Project
Country of work: Uganda
What is your motivation for engaging in HIV cure and remission research?
The HIV epidemic remains one of the most daunting public health concerns the world has to tackle. Sub Saharan Africa still experiences about two thirds of all new infections each day. For over 7 years now, I have been involved with HIV care and management, HIV prevention, remission and care research. Access to treatment, side effects, poor adherence, emergence of drug resistance, and overall poor quality of life remain challenges. A cure for HIV is the ultimate hope that we need to end the epidemic. HIV remission on the other hand would benefit patients’ quality of life and national economies.
What is your current area of research?
Infectious diseases including HIV and emerging and re-emerging infections. I am sub investigator on two studies investigating possibilities of HIV cure strategies, a Phase I clinical trial evaluating the safety and virologic effect of an experimental human monoclonal antibody, alone or in combination with antiretroviral therapy, in adults during early acute HIV infection and the Early Capture HIV Cohort (ECHO) study which aims to diagnose early acute HIV infection, and how early treatment limits the establishment of latent reservoirs. I have been sub investigator on several HIV vaccine clinical trials and principal investigator for an Ebola vectored vaccine clinical trial.